ForeSENTIA: Glioma
ForeSENTIA Glioma panel tests for single nucleotide variants, insertions, deletions, copy number alterations, and rearrangements in 22 genes which are commonly found in gliomas. Glioma is a type of brain tumour that starts from the glial cells, and they account for about 30% of all primary brain and central nervous system (CNS) tumours. In 2020, more than 300,000 people were diagnosed with brain and CNS tumours worldwide. There are different types of gliomas – such as glioblastoma, an aggressive brain tumour. Studies have shown that glioma can be caused by different factors such as environmental and inheritance. Different mutations have been identified in genes such as IDH1, IDH2, TP53, and others and can be responsible for cancer initiation and development.
1p/19q codeletion is also tested in this panel and reported only in the context of glioma diagnosis. This is a genetic loss in which the short arm of chromosome 1 is deleted along with the long arm of chromosome 19. It is considered a prognostic biomarker predictive for therapy response. Indeed, it has been found that patients with this codeletion have improved prognosis and overall survival after treatment.
Microsatellite instability (MSI) immunotherapy biomarker can optionally be tested in this panel. MSI has also been detected in patients with glioma and can be tested in this panel.
Created by
Our editorial team consists of medical specialists and scientists in the field of human genetics. All content is created and reviewed in accordance with current scientific standards.
Are you a patient?
Certified laboratories
